Truist upgrades Evolent Health to Buy, keeps $6 price target
Truist Securities raised its rating on Evolent Health shares to Buy from Hold and kept its price target at $6.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Truist Securities upgraded Evolent Health shares to Buy from Hold and left its price target unchanged at $6, according to TradingView, which cites data from Benzinga. The target implies a 74.9% gain from the November 19 close of $3.43.
why it matters
A single broker upgrade usually moves only the stock in question and rarely shifts the broader market. Investors typically check whether the target rests on the company's expected results.
tags
instruments
sources
- Truist Securities upgrades Evolent Health to Buy from Hold, keeps price target at $6 — TradingView, 20 November 2026 at 13:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗